|
|
|
|
|
Legal status
Patent expired
| (51) | INT.CL. | C07K 14/705 | (2006.01) |
| G01N 33/68 | (2006.01) |
| (11) | Number of the document | 1536234 |
| (13) | Kind of document | T |
| (96) | European patent application number | 04008908.8 |
| Date of filing the European patent application | 2001-05-23 | |
| (97) | Date of publication of the European application | 2005-06-01 |
| (45) | Date of publication and mention of the grant of the patent | 2016-03-16 |
| (46) | Date of publication of the claims translation | 2016-06-10 |
| (30) | Number | Date | Country code |
| 579927 | 2000-05-26 | US | |
| 214065 P | 2000-06-26 | US |
| (72) |
Peach, Robert J., US
Naemura, Joseph R., US
Linsley, Peter S., US
Bajorath, Jürgen, US
|
| (73) |
Bristol-Myers Squibb Company,
Route 206 and Province Line Road, Princeton, NJ 08543,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Tirpios CTLA4 mutantinės molekulės ir jų panaudojimas |
| Soluble CTLA4 mutant molecules and uses thereof |
| Payment date | Validity (years) | Amount | |
| 2020-04-23 | 347.00 EUR |